You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Co-Diagnostics' test, which recently received Emergency Use Authorization in the US, is designed to detect the RdRp gene of the SARS-CoV-2 virus.
The companies have signed on to a new public-private initiative organized by Wisconsin's governor intended to increase the state's testing capacity.
Promega said it plans to use the technology to create new research products for investigating endogenous biology.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
Verogen's ForenSeq kit and Thermo Fisher Scientific's Precision ID Whole Genome Panel can now be used to create DNA profiles for a national repository.
The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.
Promega said it will combine the CRISPR technology with its own products that are designed for knock-in of genetic reporters into cells or cell lines.
Of the six kits, the team found that Qiagen and Norgen's spin column tools recovered the highest amount of DNA across a range of base pair lengths.
This week's news includes MolecularMD, Agendia, Promega, and NRGene.
The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.